Study on The Intervention Effect on Patients with Dyslipidemia of Dampness Syndrome
- Conditions
- Dyslipidemia
- Registration Number
- ITMCTR2200006576
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1.18-70 years old.
2.Those who meet the typical diagnosis of dampness syndrome in the Diagnostic Standard of Dampness Syndrome of Traditional Chinese Medicine V2.0.
3.Those who meet the diagnosis of dyslipidemia in the guidelines for Prevention and Treatment of Dyslipidemia in Chinese Adults (2016 revised Edition).
4.Patients whose cardiovascular risk assessment is medium risk and low risk.
5.Those who volunteer to participate in the study of this subject and sign informed consent forms.
1. Patients with nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, myeloma, glycogen accumulation, lipoatrophy, acute porphyria and polycystic ovary syndrome.
2. Patients who are using drugs related to blood lipid metabolism, such as diuretics, beta blockers, glucocorticoids, metformin, insulin, contraceptive.
3. Patients with systolic blood pressure = 180mmHg or diastolic blood pressure = 110mHg after treatment.
4. Patients whose fasting blood glucose was still = 11.1mmol/L after oral drug treatment.
5. Patients whose TG = 5.65mmol/L.
6. Patients with systemic severe diseases such as heart, liver, kidney, hematopoietic system, immune system, etc.
7. Pregnant or lactating women or people who plan to become pregnant during the trial or whose spouse plans to become pregnant.
8. Patients with allergic constitution, who may be allergic to this drug or who are mentally ill.
9. Other patients who can't cooperate for a long time.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome: High density lipoprotein cholesterol (HDL-C);Cardiovascular risk assessment;Triglyceride (TG);Score of Dampness Syndrome Scale;Low density lipoprotein cholesterol (LDL-C);Total cholesterol (TC);
- Secondary Outcome Measures
Name Time Method HbA1c;Fasting insulin;Interleukin-6;Body mass index (BMI);Insulin resistance index;C-reactive protein (CRP);Blood pressure;Tumor necrotic factor-a (TNF-a);Fasting plasma glucose;Intestinal flora;Uric acid (UA);Insulin action index;